Compare Baxter International Inc (BAX) vs Freeport-McMoRan Inc (FCX) Price & Performance

Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.

BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.

FCX trades at $59.98, down 2.51% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and a 10.34% net income margin highlight operational strength. The stock faces near-term resistance at $61, with support at $59. Analysts maintain a $72.94 consensus target, reflecting 22% upside potential. Copper demand growth and expansion projects support long-term prospects.

Outlook remains positive driven by copper's structural supply-demand imbalance and FCX's cost leadership. Risks include commodity price volatility and execution challenges in new projects. Institutional sentiment is bullish with 59% buy ratings, though technical indicators suggest near-term consolidation. The dividend yield of 0.25% provides modest income support.